20.7 C
New York
Tuesday, August 16, 2022
HomeBusiness NewsBioCryst Pharmaceuticals, Inc. (BCRX) Cheers on Receiving Funding For Non-Human Primate Study...

BioCryst Pharmaceuticals, Inc. (BCRX) Cheers on Receiving Funding For Non-Human Primate Study

Date:

Related stories

Silicon Valley Stunned by the Fulminant Slashed Investments

I actually first read this as alkalizing meaning effecting...

The Next Wave of Superheroes Has Arrived with Astonishing Speed

I actually first read this as alkalizing meaning effecting...

Watch Awesome Kate Halle Go Full Wiming Pro in the Bahamas

I actually first read this as alkalizing meaning effecting...

The Weirdest Places Ashes Have Been Scattered in New Zeeland

I actually first read this as alkalizing meaning effecting...

The Car Insurance Catch that can Double Your Cover in Two Months

I actually first read this as alkalizing meaning effecting...
spot_imgspot_img

BioCryst Pharmaceuticals, Inc. (BCRX) reported on Friday that the National Institute of Allergy and Infectious Diseases or NIAID has received a contract modification for an extra $2.4M to the firm to conduct a dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates because a treatment for Ebola virus disease. The study is anticipated to be initiated within weeks.

The firm declared that the successful completion of an efficacy study in an tentative Ebola virus disease model in non-human primates signifies an important next step towards understanding the possible of BCX4430 as a treatment for Ebola disease in humans. NIAID, division of the National Institutes of Health, granted an agreement to BioCryst in September 2013 valued up to $22.0M over 5 years.

By means of this further award, the BCX4430 development agreement has been rose in value to $24.4M, if all options are exercised.

The victorious completion of a worth full study in an experimental Ebola virus disease model in non-human primates represents an important next step towards understanding the possible of BCX4430 as a treatment for Ebola disease in humans. NIAID, part of the National Institutes of Health, granted a agreement to BioCryst in September 2013 worth around $22M more than five years.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img